RE:RE:Something to think about...EbbFlow88 wrote: EbbFlow88 wrote: Something I can't stop thinking about is that the current market cap is around $585M assuming 112.5M shares outstanding at the current price.
Biotoscana was purchased for $369M CAD and Exelon was purchased for $217M CAD. Neither of which was purchased at a high multiple. Total purchases of those two assets = $586M
Excluding the recent debt deal, substract cash + equivalents and financial assets from Mcap and you get ~290M CAD for GBT and drugs.
585 - 145 - 150 = 290M
So, at today's price, buyers are getting those assets at .50 on the dollar for what was paid, which our frugal management team deemed worth the purchase.
Also, ~45M in cash from Ops is a return on that 290M of 15.5%
Either they way overpaid for those assets (as chianchin most definitely believes) or this is an unbelievable gift from the market. My money is on the latter.
If you believe that tthe tax assessment will go our way. You can add 46M to our cash total. Making the market value of the base operations ~$250M which yields 18% cash.
Separately, there has been no filings for stock buybacks last month. Usually, at this point in the following month that has been filed. Maybe it's late or maybe we stopped buying back shares.
No question that volume has dried up in January. So, if we're done buying at the moment along with new $50M CAD in debt, maybe we're closer to M&A deal.
Some kind of deal - even if it's small would seem logical in 2023.
I know a small pharma that's getting regular requests to tie up for their heavy bank account and that's only $42 MM.
Thinking, GUD should be able to work this environment to their favor and pick up some assets.
Let's see.